InnoCare Pharma, a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that BTK inhibitor orelabrutinib has been granted priority review...
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced that China's National...
